Ostarine vs Anavar: complete comparison (SARM vs mild oral AAS, cutting)
| Critère | ostarine | anavar |
|---|---|---|
| Class | Non-steroidal SARM | Oral 17α-alkylated AAS |
| Route | Oral | Oral |
| Hepatotoxicity | Possible moderate | Moderate (17α-alkylated) |
| Aromatization | No | No |
| HPG axis suppression | Moderate | Moderate |
| Typical dose | 15-25 mg/d | 40-80 mg/d |
| Human studies | Phase 2 (Dalton 2011) | HIV/burn RCTs (Strawford, Wolf) |
| Female dose | 5-10 mg/d | 5-10 mg/d |
Quand choisir ostarine
Ostarine (enobosarm, MK-2866) is the most studied SARM in humans: Dalton 2011 (phase 2, 120 elderly patients) demonstrated +1.4 kg lean mass at 3 mg/d × 16 weeks with functional improvement. Choose it for: (1) a first mild SARM cycle, (2) a preservation cycle in deep cut (anti-catabolic effect in caloric deficit), (3) a 'recomp' cycle with modest mass gains and simultaneous fat loss, (4) a complement to an AAS cycle for finish, (5) an alternative to anavar with theoretically less aggressive hepatic profile. Pharmacological profile (Solomon 2019, Bhasin 2009): non-steroidal SARM, muscular selectivity, no aromatization, moderate HPG suppression. Drawbacks (Pope 2014): possible ALT/AST elevations (5-15% of users in 8-week cycles), slightly degraded lipid profile, suppression of endogenous testo 30-50% at 25 mg/d. Typical dose 15-25 mg/d × 8-12 weeks, single morning intake. Mild PCT nolvadex 20 mg/d × 4 weeks. Acceptable in women at 5-10 mg/d with virilization monitoring. Human corpus is limited but coherent.
Quand choisir anavar
Anavar (oxandrolone) is the mildest oral AAS in the AAS landscape, and the only one supported by quality human clinical trials: Strawford 1999 (RCT in HIV-wasting patients, +1.3 kg lean mass vs placebo) and Wolf 2006 (RCT in major burn patients, improvement in healing and body composition) demonstrate clear anabolic efficacy without major toxicity at therapeutic doses (10-20 mg/d × 12 weeks). Choose it for: (1) deep cuts with anti-catabolic effect preserving lean mass in caloric deficit, (2) women (5-10 mg/d is the near-non-virilization window), (3) a light oral kickstart of an injectable cycle, (4) an athlete in competitive finish seeking visual hardness without retention. Very weak androgenic profile (ratio 322:24, Kicman 2008): little risk of acne or hair loss compared to other orals like dianabol or anadrol. Drawbacks to anticipate (Niedfeldt 2018): very real hepatotoxicity despite the 'anavar safe' myth (oxandrolone classified as 17α-alkylated with moderate hepatic risk, with ALT/AST elevations in 20-30% of users on 12-week cycle), clearly degraded lipid profile even on short cycles (HDL crash sometimes > 30%). Limit to 6-8 weeks, ALT/AST and lipid monitoring every 4 weeks. Typical dose 40-80 mg/d in men, 5-10 mg/d in women. Always on testosterone base in men (otherwise probable erectile dysfunction beyond W3).
Combinaison ?
The ostarine + anavar combo is widespread in mild cutting cycle, particularly in women or users seeking qualitative gains without stacking toxicity: ostarine 15-20 mg/d + anavar 30-50 mg/d × 6-8 weeks. Both compounds target lean mass preservation in caloric deficit and visual hardness, with complementary mechanisms (muscular selective non-steroidal SARM + mild oral DHT-derivative AAS). Cumulated moderate suppression (anavar + ostarine ≈ equivalent of a testo 200-300 mg/week cycle in terms of HPG axis suppression). PCT nolvadex 20-40 mg/d × 4-6 weeks suffices in most cases (no hCG needed because suppression not deep). Biological monitoring: ALT/AST, complete lipids, T total at W0, W4, W8 (both compounds can elevate transaminases, mandatory monitoring; lipid profile can be clearly degraded under anavar). Hepatoprotectors (TUDCA 500 mg, NAC 600 mg) recommended as support. For women in solo cycle: ostarine 5 mg/d + anavar 5-10 mg/d × 4-6 weeks is a frequent cutting combination with acceptable virilization risk (weekly monitoring of androgenic signs). Sample 8-week recomp timeline for women: W0 baseline complete panel + virilization assessment (acne baseline, voice recording, hirsutism scoring), W1 ostarine 5 mg/d + anavar 5 mg/d start, W2 first virilization check (subjective + photo documentation), W4 ALT/AST + lipids + T total + virilization recheck, W6 mid-cycle full panel, W8 last dose, W9 PCT start (nolvadex 20 mg/d × 3 weeks), W14 post-PCT recovery confirmation. Sample for men: ostarine 20 mg/d + anavar 50 mg/d × 8 weeks, same monitoring schedule with focus on ALT/AST and lipids. Independent lab testing for both compounds: critical given variable underground market — anavar mislabeling rate as high as 40% per some analyses.
FAQ
- Ostarine or anavar for women?
- Both are among the most tolerable options for women, with slight advantage to ostarine for lower virilization risk (non-steroidal, strong muscular selectivity). Anavar remains the historical standard in women (5-10 mg/d × 6 weeks with rare virilization in this window). Ostarine emerging as a milder oral alternative (5-10 mg/d × 8 weeks). Choice depends on practical preference: anavar better empirically documented, ostarine more recent corpus. Weekly virilization monitoring with both: acne, voice, hirsutism, clitoral hypertrophy.
- Is ostarine 'safer' than anavar?
- Theoretically yes (no 17α-alkylated structure, muscular selectivity), but human corpus is limited (Dalton 2011 phase 2 over 16 weeks remains the longest study). Anavar has 50+ years of clinical and empirical data. In practice, ostarine appears better tolerated hepatically in the majority of users, but DILI cases under SARMs (including ostarine) have been reported. Net: modest advantage to ostarine on theoretical hepatic profile, but no compound is 'harmless'.
- How much gains with ostarine + anavar?
- In moderate cut 8 weeks (ostarine 20 mg/d + anavar 50 mg/d) in intermediate user: +2 to +4 kg net lean mass and -2 to -3 kg fat, or net body recomposition of 4-7 kg of change. Modest strength up +5-10%. Dry profile without retention. For users not wanting to do a classic AAS cycle, it is one of the most effective combinations with acceptable tolerance profile.
- Do you need PCT after ostarine + anavar cycle?
- Yes, in most cases. Both compounds moderately suppress the HPG axis (cumulative ≈ equivalent of a testo 300 mg/week cycle). PCT: nolvadex 20-40 mg/d × 4-6 weeks, start 3-4 days after last intake (both have short half-lives). No hCG needed (non-deep suppression). T total, LH, FSH, ALT/AST panel at W6 post-PCT. If T < 300 ng/dL, extend PCT to 6 weeks.
- Ostarine or anavar for the first time?
- Anavar for male users wanting a faster visible effect (more marked gains on short cycle 6-8 weeks). Ostarine for users wanting a milder profile or a longer cycle (12 weeks possible). For women: ostarine in first intention if authentic available, otherwise anavar remains the safe standard. Any first SARM or oral AAS cycle: biological monitoring before and after (CBC, transaminases, lipids, T total).
- What monitoring for these compounds?
- Complete panel W0 (baseline): CBC, ALT/AST/GGT, bilirubin, complete lipids, T total, LH, FSH, creatinine. Intermediate panel W4: ALT/AST, lipids, T total. End of cycle panel W8: complete. Post-PCT panel W6 post-cycle: T total, LH, FSH, ALT/AST to confirm recovery. Subjective monitoring: libido, energy, sleep disorders, breast sensitivity (possible gyno under anavar although rare).
- How to verify product purity?
- Anavar: prefer authentic pharma (Spitfire, Hubei, etc. per availability) or reputable UGL with public tests. Frequent cases of products containing dianabol or winstrol sold as anavar. Ostarine: underground market with 30-60% of underdosed or contaminated products per independent analyses. Lab tests (Janoshik, AnaboLab) recommended before important cycle. The cost of a test (~50 €) is negligible compared to risk.
- Does ostarine combined with anavar aromatize?
- No. Neither ostarine nor anavar aromatize to estrogen: ostarine is non-steroidal, anavar is a DHT-derivative (17α-methyl, 1-dehydro). No risk of E2 elevation or gynecomastia under this combo. No AI needed. If a testosterone base is added to the cycle, dose-dependent AI on the latter (anastrozole 0.5 mg 2× per week titrated on measured E2).